Biotin

Clinical Summary

Biotin (vitamin B7) is a water-soluble B-vitamin that serves as an essential cofactor for four carboxylases involved in fatty acid synthesis, gluconeogenesis, and amino acid catabolism. It is one of the most overhyped supplements on the market — massively promoted for hair growth despite zero RCT evidence in non-deficient individuals.

Where biotin genuinely matters: Biotinidase deficiency (rare genetic condition — lifelong biotin prevents devastating neurological damage), brittle nail syndrome (modest evidence from small trials), and as an adjunct to chromium for T2D glucose control (moderate evidence). High-dose use for MS (MD1003, 100-300 mg/day) was abandoned after the Phase 3 SPI2 trial failed its primary endpoint in 2020 (PMID: 33222767).

The real danger of biotin isn't toxicity — it's lab interference. At doses >1 mg/day, biotin interferes with immunoassays using biotin-streptavidin technology, causing false troponin (missed heart attacks), false thyroid panels, and false tumor markers. The FDA issued a safety communication after at least one death from a falsely negative troponin. This is dose-dependent and extends to allergy diagnostics (IgE), ELISA research kits, and preeclampsia markers (PlGF).

New findings (2024-2026): Two UK Biobank studies now link dietary biotin to dementia risk: the original (n=122,959, PMID: 40914826) showing 25-33% reduced risk, and a follow-up (PMID: 41679193) providing the first mechanistic link — biotin interacts with PSEN1 catalytic pocket and APOE receptor-binding domain, with mouse validation showing biotin deficiency elevates Aβ42. Still observational + animal, but the mechanistic chain strengthens. A contrarian mouse study (PMID: 40439440) found biotin-free diet reduced arthritis via microbiome mechanisms. New safety signal: a rechallenge-confirmed case of proximal renal tubular acidosis at just 2.5 mg/day in a 16-year-old (PMID: 41835731). Lab interference research expands to IgE allergy diagnostics and preeclampsia markers — but next-gen assays (Roche hs-cTnT Gen 6) now resist biotin up to 1200 ng/mL (PMID: 41885135).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Key insight: Unlike most nutrients, supplemental biotin has HIGHER bioavailability than food-derived biotin because it's provided in free form, bypassing enzymatic hydrolysis. Standard oral capsules are optimal for all uses.

Safety

Interactions Table

Contraindications

• Absolute: None
• Relative: Upcoming lab testing (stop high-dose biotin first); active cardiac event evaluation (troponin interference); high-risk cardiac patients on >1 mg/day

Adverse Effects (ranked by frequency)

• None consistently reported at standard doses (30-5000 µg/day)
• Uncommon: Nausea, mild diarrhea (doses >10 mg/day)
• Rare: Acne/breakouts (anecdotal, dose-dependent, possibly via B5 competition and/or excess keratin production — community reports ~20-30% at >2.5 mg)
• Rare: Sleep disruption — nightmares (0.26% of 33,728 users per eHealthMe) and insomnia reported; take in morning
• Case report (2025): High-dose biotin exacerbated chronic migraine (PMID: 41450445)
• Case report (2026, rechallenge-confirmed): Proximal renal tubular acidosis (type 2) in 16-year-old female at just 2.5 mg/day — severe hypokalemia, hyperchloremic metabolic acidosis, glucosuria; resolved on cessation, reproduced on rechallenge (PMID: 41835731). First documented case; single report but rechallenge strengthens causality.
• Serious (overall): Very rare. The RTA case above is the first documented serious AE at standard therapeutic dose. Doses up to 300 mg/day used in MS trials for years without significant toxicity beyond lab interference.
• No established UL: No upper limit set by IOM due to lack of toxicity data

FAERS Signal Table (from BioMCP)

Reading FAERS data: The ~68,759 total biotin FAERS reports are overwhelmingly from multi-ingredient products (prenatal vitamins, multivitamins, IV nutrition, hair supplement formulations) where biotin is listed as suspect by default. Only 1 report lists biotin as the sole primary suspect drug (blister, quality of life decreased, rib fracture — Serious). The top co-reported drug is minoxidil (32,508 reports), confirming the alopecia-indication overlap. "Drug ineffective" as the #1 reaction confirms most reports reflect biotin's lack of efficacy for hair loss, not true adverse events. The dominant real-world safety signal (lab interference) is NOT captured in FAERS coding. Per the FAERS supplement noise pattern, this data is largely non-informative for biotin-specific risk assessment.

Monitoring Table

Laboratory Test Interference — Detailed

Mechanism: Modern immunoassays use biotin-streptavidin technology. High plasma biotin competes with assay biotin, causing false results. Direction depends on assay design (competitive vs sandwich).

Life-threatening consequences:

Assay evolution (good news): The Roche hs-cTnT Gen 6 assay (2026) shows no interference up to 1200 ng/mL biotin — a major improvement over prior generations (PMID: 41885135). As labs upgrade, troponin interference will diminish. However, TSH/thyroid, cancer markers, IgE, and PlGF assays have NOT been universally redesigned yet.

Washout by dose:

Synergies & Stacking

Antagonisms:

• Avidin (raw egg whites): binds biotin with Kd ~10⁻¹⁵ M — one of strongest non-covalent bonds in nature
• Alpha-lipoic acid (>600 mg): competes for SMVT transporter (2/5, theoretical)

Individual Response Modifiers

Sex-Specific Considerations

Sex-specific pharmacokinetics: No dedicated studies exist. This is a research gap.

Genetic Modifiers

General population pharmacogenomics: No data exists on common genetic variants modifying biotin response in non-deficient individuals. All pharmacogenomic literature relates to rare inborn errors of metabolism. This is a significant research gap.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance. Last surveyed: 2026-04-14.

Dominant Sentiment

Mixed to polarized across ~1000+ reports. Drugs.com rating: 5.4/10 (54 reviews: 41% positive, 39% negative). Nail communities most positive; skincare communities most negative; hair loss communities skeptical. Longecity longevity community does NOT consider biotin a longevity compound (absent from all 2025 longevity reviews). Consumer skepticism rising: Consumer Reports, Cleveland Clinic, and GoodRx all published pieces in 2025-2026 questioning biotin supplement value.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: YES — SugarBearHair and similar hair gummy brands use influencer affiliate networks resembling MLM structures. Celebrity endorsements (Kardashians) create false social proof.
• Influencer concentration: HIGH — hype driven by paid beauty/wellness influencers with affiliate commissions, not broad organic community experience.
• Astroturfing signals: Suspicious clusters of 5-star Amazon reviews coinciding with product launches; template-style reviews across platforms. Instagram study (PMC 9762852): of 100 HSN supplement posts, only 4% from verified accounts and only 1% showed Supplement Facts label.
• Commercial bias: Positive reports strongly correlated with affiliate links. Supplement industry promotes 5,000-10,000 µg doses (167-333x AI) without evidence that higher doses work better.
• Dosage inflation: Products contain up to 650x the RDI (per FDA). No clinical basis for megadosing in non-deficient individuals.
• Acne risk suppression: Marketing materials rarely mention the ~20-30% acne incidence. Side effect information buried or minimized.
• Lab interference underreporting: Product labels rarely warn about lab test interference despite FDA safety communication.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on three points: nail improvement is the most reliable benefit, hair regrowth in non-deficient individuals doesn't happen, and acne is a real side effect (though no RCTs have quantified it). Community experience diverges from clinical data primarily on dosing — users take 167-333x the AI without evidence of dose-response beyond adequacy. The most likely explanation for divergence on hair claims is a combination of placebo effect, attribution error (concurrent treatments, natural hair cycle variation), and selection bias in self-reports. The B5 co-supplementation strategy for acne prevention is community-derived and mechanistically plausible (SMVT competition + excess keratin clogging pores) but has no oral RCT validation (note: one 2025 RCT confirmed IM pantothenic acid reduces acne, but this doesn't validate the oral co-supplementation protocol). Japanese dermatological use of biotin for atopic/seborrheic dermatitis is a clinical practice not well-reflected in Western literature. Korean market has evolved toward biotin+B5 combo products — arguably more rational than Western megadose monoculture. The overall narrative is shifting: consumer skepticism toward biotin-for-hair is rising in 2025-2026, driven by dermatologist pushback and media coverage.

Deep Dive: Mechanisms & Research

Key Mechanisms (with clinical translation status)

Carboxylase cofactor (CLINICAL TRANSLATION: YES): Biotin is essential for four carboxylases — acetyl-CoA carboxylase (fatty acid synthesis), pyruvate carboxylase (gluconeogenesis), propionyl-CoA carboxylase (amino acid catabolism), β-methylcrotonyl-CoA carboxylase (leucine catabolism). Deficiency of any causes metabolic crisis. Supplementation corrects deficiency but does NOT enhance function beyond saturation. Once carboxylases are fully biotinylated, excess biotin provides zero additional catalytic benefit.

Gene expression regulation (CLINICAL TRANSLATION: PARTIAL): Biotin modulates NF-κB, Sp1/Sp3 transcription factors and influences histone biotinylation (H2A, H3, H4). A 2024 Japanese review (PMID: 39125325) details anti-inflammatory effects via NF-κB suppression. Clinical significance beyond deficiency correction is unclear.

Glucose metabolism enhancement (CLINICAL TRANSLATION: PARTIAL): Biotin activates glucokinase expression and enhances insulin sensitivity via AMPK pathway. Clinical effect modest (FBG -20-45 mg/dL) and best demonstrated with chromium co-administration.

Neuroprotection via manganese detoxification (CLINICAL TRANSLATION: NO — preclinical only): Biotin mitigates manganese-induced Parkinson's-like neurotoxicity in Drosophila and human neurons in vitro (PMID: 39836750, Sci Signal 2025). Mechanism: biotin-dependent carboxylases maintain mitochondrial function under Mn stress. This is the first evidence linking biotin to neuroprotection beyond the failed MS hypothesis. However, Drosophila + in vitro human neurons ≠ human clinical data. No interventional studies exist.

Amyloid processing hypothesis (CLINICAL TRANSLATION: PARTIAL — mechanistic + observational): A 2026 study (PMID: 41679193) combined UK Biobank epidemiology with mouse models and molecular docking. Higher dietary biotin → reduced all-cause dementia (HR 0.78) and AD (HR 0.79) but NOT vascular dementia. Molecular docking shows biotin interacts with PSEN1 catalytic pocket and APOE receptor-binding domain. In mice, biotin deficiency elevated Aβ42 and increased Aβ42/40 ratio. Neuroimaging reveals "pseudo-atrophy" (reduced cortical volume + increased tissue intensity = structural remodeling, not degeneration). First mechanistic link between biotin and amyloidogenic processing. Still observational + animal — interventional confirmation needed.

Colonic miRNA regulation (CLINICAL TRANSLATION: NO — animal only): Biotin deficiency alters 26 colonic miRNAs, with miR-190a-5p and miR-199a-5p suppressing ZO1 (tight junction) and LGR5 (stem cell marker), implicating biotin in gut barrier integrity and inflammatory pathways (NLRP3, calprotectin) (PMID: 41754129). Extends the NF-κB story.

Myelin synthesis hypothesis (CLINICAL TRANSLATION: NO): Proposed mechanism for MS — biotin activates acetyl-CoA carboxylase to enhance myelin repair. Phase 3 SPI2 trial (PMID: 33222767) failed to demonstrate clinical benefit. A 2022 preclinical study (PMID: 36555377) showed MD1003 accelerated oligodendrocyte differentiation in mice, but this did not translate to human benefit. MD1003 also failed in AMN (NCT02961803), ALS (NCT03114215, NCT03427086), and demyelinating neuropathies (NCT02967679).

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status (from BioMCP)

• FDA: No standalone drug approval. Dietary supplement under DSHEA. Approved only as component of IV multivitamin formulations (NDA021265 — Infuvite Pediatric). Two safety communications on lab interference (2017, 2019 update).
• EMA: No medicinal product authorization. Food supplement under EU food law.
• France: Qizenday (300 mg biotin) was available under temporary authorization for progressive MS — withdrawn after SPI2 failure.
• Japan/Korea/Taiwan: Available as food supplement. Japanese dermatologists prescribe biotin (ビオチン散) for dermatitis — a clinical use less common in the West.
• Regulatory context: MD1003 development was abandoned for commercial + efficacy reasons (Phase 3 failure), not safety. Biotin as a supplement has no patent protection, so there is no commercial incentive to pursue drug approval.

New Research (2024-2026)

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Hasty generalization (HIGH): Brittle nail evidence (N<100, open-label, 1989-1993) inflated to 4/5 in prior version. Corrected to 3/5.
• Cherry-picking (HIGH): MS evidence cited positive pilot studies while insufficiently weighting the definitive Phase 3 SPI2 failure. Corrected from 3/5 to 2/5.
• Appeal to nature (HIGH): "It's a natural vitamin" conflates safety with efficacy. Biotin IS safe; excess supplementation IS useless in non-deficient individuals.
• Argument from popularity (HIGH): "Millions take it for hair" — argument from popularity. No RCT evidence in non-deficient.
• Extrapolation error (MEDIUM): "Biotin is involved in energy metabolism → supplementation boosts metabolism." Involvement ≠ rate-limiting. Enzymes have finite binding sites.

Evidence Gaps

1. No RCTs for hair growth in non-deficient individuals — the most marketed use has zero clinical support (5+ completed trials are multi-ingredient, making biotin's contribution unresolvable)
2. No sex-specific pharmacokinetic studies — biotin research doesn't stratify by sex
3. No common-variant pharmacogenomics — all genetic data relates to rare inborn errors
4. Brittle nail evidence is 30+ years old — N<100, no placebo control, no modern replication
5. Biotin + chromium synergy mechanism not fully elucidated — clinical benefit observed but molecular interaction unclear; umbrella review (PMID: 39828265) ranks biotin below vitamin C and folate for T2D
6. Dementia association strengthened but still pre-interventional — now 2 UK Biobank studies + mouse model + molecular docking (PSEN1/APOE), but no RCT testing biotin supplementation for dementia prevention
7. Neuroprotection entirely preclinical — Parkinson's data (PMID: 39836750) is Drosophila + human neurons in vitro only
8. Acne/breakout incidence never quantified in an RCT — ~20-30% community estimate has no clinical validation; third mechanism (excess keratin clogging pores) proposed but untested
9. Biotin-microbiome-gut barrier axis emerging — mouse arthritis study (PMID: 40439440) + colonic miRNA data (PMID: 41754129) suggest biotin modulates gut barrier via miR-190a/ZO1, but zero human data
10. RTA signal needs replication — single rechallenge-confirmed case (PMID: 41835731) at 2.5 mg; mechanism unknown; is this idiosyncratic or dose-dependent?

Bias Flags (Mode 4: First Principles)

• Core principle: Enzymes have finite binding sites. Once carboxylases are fully biotinylated (which happens at dietary intake levels in healthy people), excess biotin provides ZERO additional catalytic benefit. The entire supplement industry premise — that more biotin = better function — violates enzyme kinetics.
• Deficiency correction ≠ enhancement. Fixing a deficiency restores normal function. Supplementation above normal does not enhance beyond baseline. This principle is consistently violated in biotin marketing.
• Lab interference is dose-dependent physical chemistry — not a theoretical concern. Biotin-streptavidin binding is among the strongest non-covalent interactions in nature (Kd ~10⁻¹⁵ M).

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: EXTREME. Hair/skin/nails supplement market is multi-billion dollar. Biotin is the centerpiece ingredient despite zero evidence for hair growth in non-deficient individuals. Products contain 167-333x the AI to create impression that higher = better. Dosage inflation is a deliberate marketing strategy.
• Influencer economics: HIGH. Beauty/wellness influencers receive affiliate commissions (typically 10-30%) for promoting biotin gummies. SugarBearHair, Natrol, Nature's Bounty are major advertisers. Celebrity endorsements (Kardashians, etc.) create manufactured social proof.
• Counter-narrative manipulation: MINIMAL. No one profits from warning against biotin (no competing pharma product for the same indications). The FDA safety communication is credible and commercially unmotivated.
• Cui bono summary: Who wins if you take it: supplement manufacturers, MLM-adjacent brands, affiliate influencers. Who wins if you don't: nobody (there's no anti-biotin industry). This asymmetry is a strong signal that the pro-biotin narrative is commercially driven.
• Red team highlight: The single most concerning angle is #3 (cui bono): the entire biotin-for-hair market exists because of marketing, not evidence. The supplement industry created demand for a product that doesn't work for its most promoted use.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 3/10 — narrow general-population utility given the rarity of frank deficiency; meaningful utility only for documented deficiency, inherited biotinidase deficiency, biotin-responsive basal ganglia disease, or brittle nail syndrome. Dementia/neuroprotection signals remain preliminary.
• Opportunity cost: One more pill, lab interference risk (particularly relevant for anyone with pending or recent endocrine testing), mental bandwidth, financial cost — all for zero expected benefit.
• Hell Yes or No (Sivers): Definitively NO. Not even close to an enthusiastic yes.
• Regret minimization: At 80, would you regret NOT taking biotin? Absolutely not.
• Verdict: SKIP — No indication for this compound in a non-deficient biohacker without brittle nails or T2D. The most important thing about biotin for regular biomarker trackers isn't what it does for you — it's what it does to your blood tests.
• Conditional upgrade to WATCH: The dementia story is strengthening (now 2 UK Biobank studies + mechanistic validation via PSEN1/APOE docking + mouse Aβ42 data). If an interventional RCT for dementia prevention launches, upgrade to WATCH. The neuroprotection angle (Parkinson's, PMID: 39836750) is too early (Drosophila) to influence verdict.

Bottom Line

Biotin is a vitamin with genuine life-saving value for a rare genetic condition and modest evidence for brittle nails and T2D (with chromium). Everything else — hair growth, cognitive enhancement, skin health, weight loss — is marketing fiction unsupported by clinical evidence. The high-dose MS experiment is over (Phase 3 failed). The real risk of biotin supplementation isn't toxicity (it has none) but lab interference that can mask heart attacks, fake thyroid disease, and mislead cancer monitoring. For biohackers who track biomarkers: biotin supplementation above dietary adequacy is self-sabotage. Your diet almost certainly provides enough. If you have brittle nails, a 6-12 month trial of 2.5 mg/day is reasonable and low-risk. For everything else, save your money.

Practical Notes

Brands: Any product with USP Verified or NSF Certified seal. Thorne, Pure Encapsulations, NOW Foods, Life Extension, Nature Made are reliable. For budget: Kirkland (Costco), Amazon Elements with third-party COA.

Storage: Room temperature (15-25°C), protect from direct sunlight, original container, tightly closed. Shelf life 2-3 years unopened.

Cost: Standard biotin (30-100 µg) = $3-8/month. Therapeutic (2.5 mg for nails) = $8-15/month. Avoid liposomal, sublingual, and HSN formulas — unnecessary markup for no proven advantage.

Lab test timing hack: If taking >1 mg/day for any reason, schedule routine blood work and stop biotin 3-5 days prior. Resume immediately after blood draw. Brief interruption has no clinical consequence.

The "egg white injury" teaching point: Raw egg whites contain avidin which binds biotin. Cooking denatures avidin. This historical finding (1940s) led to biotin's discovery as a vitamin.

Quality red flags to avoid: No third-party testing, proprietary blends hiding amounts, unrealistic claims ("cures baldness"), no manufacturer contact, sold exclusively via MLM.

What We Don't Know

• Whether biotin supplementation benefits ANY non-deficient population for ANY indication (hair, skin, cognition, longevity — all unproven)
• Whether the UK Biobank dementia association reflects biotin itself or diet quality — now strengthened by PSEN1/APOE mechanistic data (PMID: 41679193) but still no interventional RCT
• Whether biotin's neuroprotective effect (Parkinson's model, PMID: 39836750) translates to humans
• Whether biotin-free diets reduce autoimmune arthritis in humans (mouse data only — PMID: 40439440)
• Whether the colonic miRNA / gut barrier axis (PMID: 41754129) has human relevance
• Optimal dosing for brittle nails — the 2.5 mg dose was never compared to other doses
• Whether biotin-induced acne is real and mediated by B5 competition and/or keratin overproduction (community hypothesis, no RCT)
• Whether the proximal RTA case (PMID: 41835731) is idiosyncratic or a reproducible dose-dependent effect
• How common genetic variants in SMVT/SLC5A6 affect biotin requirements in the general population
• Whether biotin supplementation alters gut microbiome composition in humans
• Whether all lab assay platforms will eventually be redesigned to eliminate biotin-streptavidin interference
• Long-term effects of megadosing (>10 mg/day) beyond the 5-year follow-up in MS trials
• Sex-specific differences in biotin pharmacokinetics, efficacy, or safety (zero data)
• Whether split dosing (Japanese practice) improves tissue saturation vs single daily dosing

References

Systematic Reviews & Meta-Analyses

1. Espiritu AI, Remalante-Rayco PPM. (2021). High-dose biotin for multiple sclerosis: SR & meta-analysis of RCTs. Mult Scler Relat Disord 55:103159. PMID: 34332461 — 3 RCTs (N=889): insufficient evidence for composite disability improvement; moderate certainty for walking speed; HIGH certainty of lab interference.

2. Zhang Y, Ding Y, Fan Y, et al. (2022). Biotin intervention on glycemic control and lipid profile in T2DM: SR & MA. Front Nutr. PMID: 36386951 — Pooled data from 5 trials shows FBG reduction; larger effects with chromium combo.

3. Patel DP, Swink SM, Castelo-Soccio L. (2017). A Review of the Use of Biotin for Hair Loss. Skin Appendage Disord 3(3):166-169. PMID: 28879195 — Only 18 case reports, ALL in deficiency states. "No evidence that additional biotin supplementation benefits patients with normal biotin levels."

4. Gaffney PJ, Gupta RK. (2025). Vitamin supplementation in optic neuritis: SR & MA. Mult Scler Relat Disord 104:106797. PMID: 41124782 — MD1003 showed no significant effect on RNFL thickness or visual acuity.

Landmark Clinical Trials

5. Cree BAC, Cutter G, Wolinsky JS, et al. (2020). SPI2: MD1003 for progressive MS — Phase 3 RCT. Lancet Neurol 19(12):988-997. PMID: 33222767 — N=642. FAILED primary endpoint (12% vs 9%, OR 1.35 [0.81-2.26]). "MD1003 cannot be recommended for treatment of progressive MS."

6. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. (2008). CrPic + biotin for T2D glucose metabolism. Diabetes Metab Res Rev 24(1):41-51. PMID: 17506119 — N=447. FBG decreased 0.54% HbA1c; more pronounced in poorly controlled patients (HbA1c ≥10%).

7. Tourbah A, Lebrun-Frenay C, Edan G, et al. (2016). MD1003 for progressive MS — Phase 3 (MS-SPI). Mult Scler 22(13):1719-1731. PMID: 27589059 — N=154. Original positive trial: 13% responder rate. Later contradicted by SPI2.

8. Hochman LG, Scher RK, Meyerson MS. (1993). Brittle nails: response to daily biotin supplementation. Cutis 51(4):303-305. PMID: 8477615 — N=35. Open-label. 63% clinical improvement; 25% nail thickness increase.

9. Colombo VE, Gerber F, Bronhofer M, Floersheim GL. (1990). Treatment of brittle fingernails with biotin: SEM. J Am Acad Dermatol 23(6 Pt 1):1127-1132. PMID: 2273113 — N=32. 25% thickness increase in treated group.

10. Floersheim GL. (1989). Treatment of brittle fingernails with biotin. Z Hautkr 64(1):41-48. PMID: 2648686 — Original Swiss study. Significant nail thickness increase on SEM.

Key Mechanism & Safety Studies

11. Sedel F, Papeix C, Bellanger A, et al. (2015). High doses of biotin in chronic progressive MS: pilot study. Mult Scler Relat Disord 4(2):159-169. PMID: 25787192 — N=23. Open-label pilot showing 89% improvement (uncontrolled).

12. Said HM. (2009). Cell and molecular aspects of human intestinal biotin absorption. J Nutr 139(1):158-162. PMID: 19056639 — Authoritative review of SMVT transporter and biotin absorption mechanisms.

13. Wolf B. (2012). Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have." Genet Med 14(6):565-575. PMID: 22241090 — 40+ years of treatment data; complete prevention if treated from birth.

14. US FDA. (2017). FDA warns that biotin may interfere with lab tests: Safety Communication. — At least one death from falsely negative troponin. Updated 2019.

15. Mock DM, Quirk JG, Mock NI. (2002). Marginal biotin deficiency during normal pregnancy. Am J Clin Nutr 75(2):295-299. PMID: 11815320 — ~50% of pregnant women develop marginal deficiency by late pregnancy.

16. Mock DM, Stadler DD, Stratton SL, Mock NI. (1997). Biotin status assessed longitudinally in pregnant women. J Nutr 127(5 Suppl):710S-716S. PMID: 9164238 — Biotin status declines progressively during pregnancy.

17. Kuroishi T. (2015). Regulation of immunological and inflammatory functions by biotin. Can J Physiol Pharmacol 93(12):1091-1096. PMID: 26222328 — Review of biotin's immune-modulating role.

18. Institute of Medicine. (1998). Dietary Reference Intakes for B vitamins. National Academies Press. — AI of 30 µg/day; no UL established.

New Research (2024-2026)

19. Kong Y, Zhong J, Wang T, Zhang D. (2025). Dietary biotin intake and dementia risk: UK Biobank (n=122,959). Mol Nutr Food Res 69(22):e70252. PMID: 40914826 — HR 0.67 (Q4 vs Q1); L-shaped nonlinear relationship; SII-mediated.

20. Sakurai-Yageta M, Suzuki Y. (2024). Molecular mechanisms of biotin in inflammatory diseases. Nutrients 16(15):2444. PMID: 39125325 — Japanese review: biotin suppresses NF-κB, modulates inflammatory cytokines.

21. Lis K. (2025). Biotin supplementation — hypersensitivity and interference in allergy diagnostics. Nutrients. PMID: 40806008 — New: IgE assay interference.

22. Valentim FO, et al. (2024). Biotin 5mg vs minoxidil 5% for hair growth in men: RCT. An Bras Dermatol. PMID: 38688776 — First dedicated biotin vs active comparator hair RCT.

23. Shemer A, et al. (2025). Biotin vs pyridoxine vs combo for onychoschizia. J Drugs Dermatol. PMID: 39913222 — New nail treatment comparison RCT.

24. Chiu KC, Jhan JR, Yan HN, et al. (2025). Biotin interference in routine clinical immunoassays. Pract Lab Med. PMID: 40417451 — Taiwanese study: comprehensive interference assessment.

25. Sanosi AA. (2025). High-dose biotin exacerbates chronic migraine: case report. Int Med Case Rep J. PMID: 41450445 — New adverse effect signal.

26. Kürkçü Kahraman E, et al. (2025). Biotin interference in pediatric ELISA kits. J Clin Lab Anal 39(16):e70079. PMID: 40657850 — Interference extends to manual research kits.

27. Pi BK, et al. (2025). SLC5A6 mutations in Korean polyneuropathy. JPNS. PMID: 40396389 — East Asian pharmacogenomic data.

28. Food Funct. (2025). Biotin-free diet attenuates collagen-induced arthritis. PMID: 40439440 — Contrarian: excess biotin may promote autoimmune arthritis via microbiome.

Lab Interference (Selected Additional)

29. Li D, et al. (2020). AACC Guidance on Biotin Interference. J Appl Lab Med. PMID: 32445355
30. Bowen R, et al. (2019). Best practices for mitigating biotin interference. Clin Biochem. PMID: 31473202
31. Favresse J, et al. (2018). Thyroid function immunoassay interferences. Endocr Rev. PMID: 29982406
32. Swallow K, et al. (2026). In-vitro verification of tolerance limits for biotin interference. Ann Clin Biochem. PMID: 41876205

Additional Key References

33. Geohas J, et al. (2007). CrPic + biotin reduces atherogenic index in T2D. Am J Med Sci 333(3):145-153. PMID: 17496732
34. Karachaliou CE, Livaniou E. (2024). Biotin homeostasis and human disorders: recent findings. Int J Mol Sci 25(12):6578. PMID: 38928282
35. Mock DM. (2005). Marginal biotin deficiency is teratogenic in mice and perhaps humans. J Nutr Biochem 16(7):435-437. PMID: 15992683
36. Zempleni J, Wijeratne SS, Hassan YI. (2009). Biotin. BioFactors 35(1):36-46. PMID: 19319844
37. Shing V, et al. (2025). Benefits and risks of HSN supplements in older adults. Int J Womens Dermatol. PMID: 41278416
38. Tourbah A, et al. (2018). MD1003 for optic neuritis in MS: RCT. CNS Drugs. PMID: 29808469 — Negative result.

New Research (2025-2026 additions)

39. Zhang D, et al. (2026). Dietary biotin → brain structural modulation and amyloid-beta pathology: insights into dementia neuropathology. EBioMedicine. PMID: 41679193 — Second UK Biobank study + mouse model. HR 0.78 for all-cause dementia; molecular docking with PSEN1/APOE; biotin deficiency elevates Aβ42.
40. Ahmad SA, et al. (2026). Biotin-induced proximal renal tubular acidosis with rechallenge confirmation. Cureus. PMID: 41835731 — 16yo female, 2.5 mg/day. First documented serious AE at standard therapeutic dose.
41. Lai Y, et al. (2025). Biotin mitigates Mn-induced Parkinson's-related neurotoxicity in Drosophila and human neurons. Sci Signal. PMID: 39836750 — First neuroprotection data beyond MS hypothesis.
42. Sabui S, et al. (2026). Biotin deficiency alters colonic miRNA expression. Nutrients. PMID: 41754129 — miR-190a-5p/ZO1 and miR-199a-5p/LGR5 gut barrier link.
43. Knoll A, et al. (2026). Analytical evaluation of hs-cTnT Gen 6 assay. J Appl Lab Med. PMID: 41885135 — No interference up to 1200 ng/mL biotin.
44. Skipper KA, et al. (2026). Biotin interference on serum PlGF measurement. Clin Chim Acta. PMID: 41285216 — Extends interference to preeclampsia diagnostics.
45. Abdulbari MS, et al. (2025). Azithromycin decreases serum biotin in acne patients. Arch Dermatol Res. PMID: 40471325 — New drug-nutrient interaction.
46. Mohammed M, et al. (2026). Screening for biotinidase deficiency in pediatric spinal cord demyelination. Mult Scler Relat Disord. PMID: 41483680 — 10.3% of children with demyelination had BTD deficiency.
47. Chai Y, et al. (2025). Water-soluble vitamins for T2D glycemic control: umbrella review. Asia Pac J Clin Nutr. PMID: 39828265 — Biotin evidence weaker than vitamin C and folate.
48. Lisci M, et al. (2026). Biotin and FBXW7 essential to bypass glutamine addiction. Molecular Cell. PMID: 41747732 — Cancer metabolism: pyruvate carboxylase activation.
49. Sechi A, et al. (2025). Safety of nutritional supplements for hair loss in breast cancer patients. Nutrients. PMID: 40362760 — Biotin "nontoxic but interferes with blood test results."